Mylan
Lobbying activity
The following activities occurred for this specific Subject Matter Area.
Event / Reception (1)
Event in European parliament organised by Medicines for Europe Trade Association on the topic of an SPC Manufacturing Export waiver.
Medicines for Europe is committed to supporting industrial policy initiatives aimed at strengthening the European industrial base, increasing investments in R&D for generic, biosimilar and value added medicines, boosting EU competitiveness, and taking up the opportunities which are opening up in Europe and worldwide. A manufacturing waiver under the Supplementary Protection Certificate (SPC) in the EU serves this purpose.
The SPC manufacturing waiver is essential for the EU. Its introduction would create 25.000 additional jobs, €3.1 billion saving in EU pharmaceutical spending and net sales of the EU based pharmaceutical industry of €9.5 billion. The fast implementation of the SPC manufacturing waiver is key to avoid further technology transfer of pharmaceutical production outside Europe and boost R&D and manufacturing investment in Europe.
Designated public officials lobbied
The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.